{"disease":{"id":"brca-mutation","name":"brca mutation"},"drugs":{"marketed":[{"drug_id":"olaparib","indication_name":"BRCA mutation-positive and HER2-negative breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lynparza","generic_name":"olaparib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Poly [ADP-ribose] polymerase 2","drug_class":"Poly(ADP-Ribose) Polymerase Inhibitor [EPC]","quality_score":73,"revenue":"2600","mechanism":"Lynparza blocks the repair of DNA damage in cancer cells by inhibiting the enzyme PARP."},{"drug_id":"talazoparib-with-enzalutamide","indication_name":"Metastatic castration-resistant prostate cancer (mCRPC) with BRCA1, BRCA2, or ATM gene mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talazoparib with enzalutamide","generic_name":"talazoparib-with-enzalutamide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PARP enzymes and androgen receptor","drug_class":"PARP inhibitor and androgen receptor inhibitor","quality_score":10,"revenue":"2194","mechanism":""},{"drug_id":"lynparza","indication_name":"BRCA mutation-positive and HER2-negative breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lynparza","company_name":"University of Texas Southwestern Medical Center","drug_phase":"marketed","molecular_target":"Mono [ADP-ribose] polymerase PARP16, Tankyrase-1, Tankyrase-2","drug_class":"","quality_score":16,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07253051","title":"BRCA Mutation Carriers' Platform a Multicenter Study","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT07039552","title":"Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT03351803","title":"BRCA Founder OutReach (BFOR) Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5412,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT02993068","title":"Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)","phase":"NA","overall_status":"SUSPENDED","enrollment_count":5200,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06429644","title":"Long-term Oncologic Outcome of Breast-conserving Surgery in Breast Cancer Patients With BRCA1/2 Mutations","phase":"","overall_status":"COMPLETED","enrollment_count":4010,"lead_sponsor_name":"Hanyang University Seoul Hospital","has_results":false},{"nct_id":"NCT04294927","title":"TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention","phase":"NA","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"University Medical Center Nijmegen","has_results":false},{"nct_id":"NCT06783127","title":"Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Santa Chiara Hospital","has_results":false},{"nct_id":"NCT03702309","title":"Liquid Biopsy Evaluation and Repository Development at Princess Margaret","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT04012229","title":"IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA)","phase":"","overall_status":"COMPLETED","enrollment_count":2295,"lead_sponsor_name":"Centre Hospitalier Universitaire de Besancon","has_results":false},{"nct_id":"NCT04585074","title":"Prospective Study of MAstectomy With Reconstruction Including Robot Endoscopic Surgery","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Severance Hospital","has_results":false},{"nct_id":"NCT04190667","title":"Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":1300,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT05769517","title":"Prediction of Germline BRCA 1/2 Genes From Healthy Ovaries","phase":"","overall_status":"RECRUITING","enrollment_count":1300,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT04095195","title":"Registry of Subjects at Risk of Pancreatic Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Associazione Italiana per lo Studio del Pancreas","has_results":false},{"nct_id":"NCT05420064","title":"An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05410951","title":"LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":800,"lead_sponsor_name":"European Institute of Oncology","has_results":false},{"nct_id":"NCT04431024","title":"Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03835793","title":"Health After eaRly Menopause Due to Oophorectomy","phase":"","overall_status":"UNKNOWN","enrollment_count":750,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT04108117","title":"Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction","phase":"","overall_status":"COMPLETED","enrollment_count":659,"lead_sponsor_name":"Severance Hospital","has_results":false},{"nct_id":"NCT06405295","title":"Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":600,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03211611","title":"Management of Women With BRCA1/2 Mutation","phase":"","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT03066856","title":"Dietary Intervention and BRCA Penetrance","phase":"NA","overall_status":"COMPLETED","enrollment_count":502,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT04296370","title":"A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":474,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT01844986","title":"Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":450,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT01945775","title":"A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":431,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02760849","title":"Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":374,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02194387","title":"Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":337,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02000622","title":"Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":302,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT05898009","title":"Contribution of Oncogenetics in Breast Cancer in Reunion Epidemiology of Breast Cancer in Reunion: Study of the Reunion Mutation on BRCA2","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Centre Hospitalier Universitaire de la Réunion","has_results":false},{"nct_id":"NCT03570125","title":"BRCA Main Home Nutritional Intervention-random Study","phase":"NA","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo","has_results":false},{"nct_id":"NCT05456919","title":"Quality of Sexual Function in BRCA Mutated Women","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","has_results":false},{"nct_id":"NCT04038905","title":"The Use of Digital Genetic Counselor (DGC) for BRCA1/2 Mutation Carrier Testing","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Igentify Ltd","has_results":false},{"nct_id":"NCT06380660","title":"Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":298,"lead_sponsor_name":"Acerand Therapeutics (Shanghai) Limited","has_results":false},{"nct_id":"NCT03470402","title":"Decision Support for BRCA Testing in Ethnically Diverse Women","phase":"NA","overall_status":"COMPLETED","enrollment_count":276,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT05748353","title":"Endocrine Disruptors and Life STILe in Breast Cancer Development","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":275,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT02983799","title":"Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":272,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02282020","title":"Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":266,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04683068","title":"Promoting Men's Adherence to BRCA1/2 Germline Genetic Testing","phase":"NA","overall_status":"COMPLETED","enrollment_count":264,"lead_sponsor_name":"European Institute of Oncology","has_results":false},{"nct_id":"NCT03286842","title":"To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":256,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04890327","title":"Web-based Family History Tool","phase":"NA","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":false},{"nct_id":"NCT04983628","title":"Molecular Profiling in Prostate Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Hellenic Cooperative Oncology Group","has_results":false},{"nct_id":"NCT05537844","title":"Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Liz-Anne Lewsley","has_results":false},{"nct_id":"NCT04651920","title":"A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":240,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT03544983","title":"Genetic Education in BRCA Families","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":240,"lead_sponsor_name":"Georgetown University","has_results":false},{"nct_id":"NCT01905592","title":"A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":216,"lead_sponsor_name":"Tesaro, Inc.","has_results":true},{"nct_id":"NCT04668521","title":"Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection","phase":"","overall_status":"TERMINATED","enrollment_count":215,"lead_sponsor_name":"Aspira Women's Health","has_results":false},{"nct_id":"NCT04651933","title":"A Training Set for the HRD Model in EOC","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT06201234","title":"Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":176,"lead_sponsor_name":"GBG Forschungs GmbH","has_results":false},{"nct_id":"NCT04055038","title":"Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":164,"lead_sponsor_name":"Blokhin's Russian Cancer Research Center","has_results":false},{"nct_id":"NCT02208375","title":"mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":159,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02184195","title":"Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"AstraZeneca","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}